Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with castration-resistant prostate cancer

Background: The CHAARTED and LATITUDE trials demonstrated a survival benefit of docetaxel and abiraterone for hormone-sensitive prostate cancer. In this study, we examined the impact of the risk stratification criteria used in the CHAARTED and LATITUDE trials on the prognosis of castration-resistant...

Full description

Bibliographic Details
Main Authors:	Sotaro Chikamatsu, Masaki Shiota, Shigetomo Yamada, Leandro Blas, Takashi Matsumoto, Eiji Kashiwagi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Format:	Article
Language:	English
Published:	Elsevier 2022-03-01
Series:	Prostate International
Subjects:	Androgen-deprivation therapy Castration-resistant prostate cancer Docetaxel Androgen receptor pathway inhibitor Risk stratification
Online Access:	http://www.sciencedirect.com/science/article/pii/S2287888222000010

Similar Items

Current status and future perspective on the management of metastatic castration-sensitive prostate cancer
by: Leandro Blas, et al.
Published: (2022-01-01)

Prognostic impact of dose reduction in androgen receptor pathway inhibitors for castration-resistant prostate cancer
by: Shigetomo Yamada, et al.
Published: (2022-03-01)

Taxane chemotherapy for hormone-naïve prostate cancer with its expanding role as breakthrough strategy
by: Masaki eShiota, et al.
Published: (2016-01-01)

Time to Castration Resistance as a Predictor of Response to Docetaxel in Metastatic Castration Resistance in Prostate Cancer
by: İlkay Gültürk, et al.
Published: (2022-11-01)

Prognostic Impact of Genetic Polymorphism in Mineralocorticoid Receptor and Comorbidity With Hypertension in Androgen-Deprivation Therapy
by: Masaki Shiota, et al.
Published: (2018-12-01)

Revision of CHAARTED and LATITUDE criteria among Japanese de novo metastatic prostate cancer patients
by: Manato Kanesaka, et al.
Published: (2021-12-01)

Effectiveness of Deferred Combined Androgen Blockade Therapy Predicts Efficacy in Abiraterone Acetate Treated Metastatic Castration-Resistant Prostate Cancer Patients after Docetaxel
by: Jian-Ri Li, et al.
Published: (2017-11-01)

A Review of the Pathophysiological Mechanisms Underlying Castration-resistant Prostate Cancer
by: Crowley F, et al.
Published: (2021-06-01)

EVALUATION OF EFFECT OF PROLONGED ACTION SOMATOSTATIN ANALOGUE – OCREOTIDE-DEPO – ON THE FOLLOWING HORMONAL AND CYTOTOXIC THERAPY IN PATIENTS WITH METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (М-CRPC)
by: S. V. Mishugin, et al.
Published: (2017-11-01)

Novel Strategies for Treating Castration-Resistant Prostate Cancer
by: David Ka-Wai Leung, et al.
Published: (2021-03-01)

Enzalutamide + androgen deprivation therapy (ADT) versus flutamide + ADT in Japanese men with castration‐resistant prostate cancer: AFTERCAB study
by: Hiroji Uemura, et al.
Published: (2022-01-01)

Data of relative mRNA and protein abundances of androgen receptor splice variants in castration-resistant prostate cancer
by: Tianfang Ma, et al.
Published: (2021-02-01)

Genomic Deletion at 10q23 in Prostate Cancer: More Than PTEN Loss?
by: Raghavendra Tejo Karthik Poluri, et al.
Published: (2018-06-01)

The castration level of testosterone and hormonal resistance of prostate cancer in androgen deprivation therapy
by: I. G. Rusakov, et al.
Published: (2020-12-01)

Castration-Resistant Prostate Cancer: From Uncovered Resistance Mechanisms to Current Treatments
by: Thi Khanh Le, et al.
Published: (2023-10-01)

Functional impact of androgen‐targeted therapy on patients with castration‐resistant prostate cancer
by: Tomasz M. Beer, et al.
Published: (2022-11-01)

The association of AR-V7 with resistance to Abiraterone in metastatic castration-resistant prostate cancer
by: Shuo Wang, et al.
Published: (2022-03-01)

Rupture of liver metastasis in high‐volume metastatic prostate cancer patient on androgen deprivation therapy combined with upfront docetaxel chemotherapy
by: Kenichi Hata, et al.
Published: (2022-11-01)

Safety and efficacy of abiraterone acetate in chemotherapy-naive patients with metastatic castration-resistant prostate cancer: an Italian multicenter “real life” study
by: Luca Cindolo, et al.
Published: (2017-11-01)

Expansion of mouse castration-resistant intermediate prostate stem cells in vitro
by: Yalan Xu, et al.
Published: (2022-07-01)

A comprehensive analysis of coregulator recruitment, androgen receptor function and gene expression in prostate cancer
by: Song Liu, et al.
Published: (2017-08-01)

Increased AR expression in castration-resistant prostate cancer rapidly induces AR signaling reprogramming with the collaboration of EZH2
by: Maryam Labaf, et al.
Published: (2022-11-01)

Targeting ADT-Induced Activation of the E3 Ubiquitin Ligase Siah2 to Delay the Occurrence of Castration-Resistant Prostate Cancer
by: Tingmang Yan, et al.
Published: (2021-04-01)

Differential Impact of TGFB1 Variation by Metastatic Status in Androgen-Deprivation Therapy for Prostate Cancer
by: Masaki Shiota, et al.
Published: (2021-05-01)

The Effect of Castration on Peripheral Autonomic Neurons Supplying Mammalian Male Genitourinary System
by: Jerzy Kaleczyc, et al.
Published: (2021-07-01)

Body composition and metastatic prostate cancer survivorship
by: Adriana M Coletta, et al.
Published: (2021-01-01)

Titration of Androgen Signaling: How Basic Studies Have Informed Clinical Trials Using High-Dose Testosterone Therapy in Castrate-Resistant Prostate Cancer
by: Steven K. Nordeen, et al.
Published: (2021-08-01)

Enzalutamide Versus Abiraterone plus Prednisolone Before Chemotherapy for Castration-resistant Prostate Cancer: A Multicenter Randomized Controlled Trial
by: Kouji Izumi, et al.
Published: (2022-07-01)

Systemic Therapies for Metastatic Castration-Resistant Prostate Cancer: An Updated Review
by: Koji Hatano, et al.
Published: (2023-10-01)

Androgen Receptor-Dependent Mechanisms Mediating Drug Resistance in Prostate Cancer
by: Marzieh Ehsani, et al.
Published: (2021-03-01)

Darolutamide: An Evidenced-Based Review of Its Efficacy and Safety in the Treatment of Prostate Cancer
by: Crawford ED, et al.
Published: (2020-07-01)

The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report
by: Fakhri Rahman, et al.
Published: (2017-04-01)

Replication study: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2018-04-01)

Registered report: androgen receptor splice variants determine taxane sensitivity in prostate cancer
by: Xiaochuan Shan, et al.
Published: (2015-09-01)

Triplet Therapy in Metastatic Castrate Sensitive Prostate Cancer (mCSPC)—A Potential New Standard of Care
by: Abhenil Mittal, et al.
Published: (2023-04-01)

Increased MYBL2 expression in aggressive hormone‐sensitive prostate cancer
by: Yuki Yoshikawa, et al.
Published: (2022-12-01)

Androgen synthesis inhibitors in the treatment of castration-resistant prostate cancer
by: Mark N Stein, et al.
Published: (2014-06-01)

Cell‐by‐cell quantification of the androgen receptor in benign and malignant prostate leads to a better understanding of changes linked to cancer initiation and progression
by: Seta Derderian, et al.
Published: (2023-07-01)

Current Status and Future Perspective on the Management of Lymph Node-Positive Prostate Cancer after Radical Prostatectomy
by: Masaki Shiota, et al.
Published: (2022-05-01)

Dissecting the Hormonal Signaling Landscape in Castration-Resistant Prostate Cancer
by: Fabrizio Fontana, et al.
Published: (2021-05-01)